265 related articles for article (PubMed ID: 23680731)
1. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats.
Yang ZZ; Zhang YQ; Wu K; Wang ZZ; Qi XR
Curr Alzheimer Res; 2012 Mar; 9(3):315-25. PubMed ID: 22044027
[TBL] [Abstract][Full Text] [Related]
3. A study of rivastigmine liposomes for delivery into the brain through intranasal route.
Arumugam K; Subramanian GS; Mallayasamy SR; Averineni RK; Reddy MS; Udupa N
Acta Pharm; 2008 Sep; 58(3):287-97. PubMed ID: 19103565
[TBL] [Abstract][Full Text] [Related]
4. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.
Mutlu NB; Değim Z; Yilmaz Ş; Eşsiz D; Nacar A
Drug Dev Ind Pharm; 2011 Jul; 37(7):775-89. PubMed ID: 21231901
[TBL] [Abstract][Full Text] [Related]
5. [Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].
Yang ZZ; Wang ZZ; Wu K; Qi XR
Yao Xue Xue Bao; 2011 Jul; 46(7):859-63. PubMed ID: 22010358
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
7. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2).
Degim Z; Mutlu NB; Yilmaz S; Eşsiz D; Nacar A
Pharmazie; 2010 Jan; 65(1):32-40. PubMed ID: 20187576
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine in Parkinson's disease dementia.
Lalli S; Albanese A
Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
[TBL] [Abstract][Full Text] [Related]
9. Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer's Disease.
Zheng X; Shao X; Zhang C; Tan Y; Liu Q; Wan X; Zhang Q; Xu S; Jiang X
Pharm Res; 2015 Dec; 32(12):3837-49. PubMed ID: 26113236
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Enz A; Gentsch C
Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
[TBL] [Abstract][Full Text] [Related]
11. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Shah B; Khunt D; Misra M; Padh H
Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
[TBL] [Abstract][Full Text] [Related]
12. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus.
Feng C; Zhang C; Shao X; Liu Q; Qian Y; Feng L; Chen J; Zha Y; Zhang Q; Jiang X
Int J Pharm; 2012 Feb; 423(2):226-34. PubMed ID: 22193058
[TBL] [Abstract][Full Text] [Related]
14. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Sang Z; Li Y; Qiang X; Xiao G; Liu Q; Tan Z; Deng Y
Bioorg Med Chem; 2015 Feb; 23(4):668-80. PubMed ID: 25614117
[TBL] [Abstract][Full Text] [Related]
16. In situ-forming oleogel implant for rivastigmine delivery.
Vintiloiu A; Lafleur M; Bastiat G; Leroux JC
Pharm Res; 2008 Apr; 25(4):845-52. PubMed ID: 17694395
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.
Liang YQ; Tang XC
Acta Pharmacol Sin; 2006 Sep; 27(9):1127-36. PubMed ID: 16923332
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
19. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
Grossberg GT
Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes.
Li W; Zhou Y; Zhao N; Hao B; Wang X; Kong P
Environ Toxicol Pharmacol; 2012 Sep; 34(2):272-279. PubMed ID: 22613079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
